Neutralization of SARS-CoV-2 BQ.1.1, CH.1.1, and XBB.1.5 by breakthrough infection sera from previous and recent waves in China

Neutralization of SARS-CoV-2 BQ.1.1, CH.1.1, and XBB.1.5 by breakthrough infection sera from previous and recent waves in China

Bibliographic Details
Main Authors:	Xun Wang, Shuai Jiang, Shujun Jiang, Xiangnan Li, Jingwen Ai, Ke Lin, Shiyun Lv, Shixuan Zhang, Minghui Li, Jixi Li, Lili Dai, Zixin Hu, Wenhong Zhang, Yanliang Zhang, Pengfei Wang
Format:	Article
Language:	English
Published:	Nature Publishing Group 2023-06-01
Series:	Cell Discovery
Online Access:	https://doi.org/10.1038/s41421-023-00569-5

Similar Items

Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters
by: Peter J. Halfmann, et al.
Published: (2024-03-01)

Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination
by: Bin Ju, et al.
Published: (2023-06-01)

Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants
by: Lorenza Bellusci, et al.
Published: (2023-04-01)

Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1
by: Fanglei Zuo, et al.
Published: (2023-04-01)

Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5
by: Kyle C. Molina, et al.
Published: (2024-08-01)

Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children
by: Lorenza Bellusci, et al.
Published: (2023-12-01)

Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2
by: Airu Zhu, et al.
Published: (2023-03-01)

In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
by: Andrei A. Pochtovyi, et al.
Published: (2023-09-01)

Subvariantes BQ.1.1 y XBB de ómicron: un problema global y estrategias de manejo
by: Sergio A. Ramírez-García, et al.
Published: (2024-01-01)

Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1
by: Shuo Liu, et al.
Published: (2023-12-01)

The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
by: Danyi Ao, et al.
Published: (2023-04-01)

In silico prediction of siRNA to silence the SARS-CoV-2 omicron variant targeting BA.4, BA.5, BQ.1, BQ1.1. and XBB: an alternative to traditional therapeutics
by: Rahatul Islam, et al.
Published: (2023-08-01)

Deep mutational scans of XBB.1.5 and BQ.1.1 reveal ongoing epistatic drift during SARS-CoV-2 evolution.
by: Ashley L Taylor, et al.
Published: (2023-12-01)

Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping
by: Masaud Shah, et al.
Published: (2023-09-01)

A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses
by: Yingdan Wang, et al.
Published: (2024-06-01)

Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1
by: Jiali Wang, et al.
Published: (2024-04-01)

Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations
by: Hak-Jun Hyun, et al.
Published: (2023-08-01)

Neutralization against XBB.1 and XBB.1.5 after omicron subvariants breakthrough infection or reinfection
by: Jin-Jin Chen, et al.
Published: (2023-04-01)

XBB.1, BQ1.1 and atypical BA.4.6/XBB.1 recombinants predominate current SARS-CoV-2 Wavelets with flu-like symptoms in Cameroon: A snapshot from genomic surveillance
by: Joseph Fokam, et al.
Published: (2024-01-01)

Broad protective RBD heterotrimer vaccines neutralize SARS-CoV-2 including Omicron sub-variants XBB/BQ.1.1/BF.7.
by: Yanfang Zhang, et al.
Published: (2023-09-01)

Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients
by: Felix Dewald, et al.
Published: (2023-05-01)

Neutralization of Omicron BA.1, BA.5.1.6, BQ.1.3 and XBB1.1 induced by heterologous vaccination Ad5-nCoV and mRNA-1273
by: Jesús Hernández, et al.
Published: (2023-04-01)

Long-term humoral and cellular immunity against vaccine strains and Omicron subvariants (BQ.1.1, BN.1, XBB.1, and EG.5) after bivalent COVID-19 vaccination
by: Hakjun Hyun, et al.
Published: (2024-05-01)

Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
by: Masayuki Amano, et al.
Published: (2023-10-01)

Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA Vaccination
by: Alexandra Tauzin, et al.
Published: (2023-01-01)

Fourth mRNA vaccination increases cross-neutralizing antibody titers against SARS-CoV-2 variants, including BQ.1.1 and XBB, in a very elderly population
by: Silvia Sutandhio, et al.
Published: (2023-07-01)

SARS-CoV-2 Variants BQ.1 and XBB.1.5 in Wastewater of Aircraft Flying from China to Denmark, 2023
by: Amanda Gammelby Qvesel, et al.
Published: (2023-12-01)

Robust neutralization of SARS-CoV-2 variants including JN.1 and BA.2.87.1 by trivalent XBB vaccine-induced antibodies
by: Xun Wang, et al.
Published: (2024-05-01)

Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants
by: Panke Qu, et al.
Published: (2023-05-01)

Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant
by: Jumpei Ito, et al.
Published: (2023-05-01)

Severity of COVID-19 sub-lineages XBB/XBB 1.5/XBB1.16, EG.5.1. and JN.1. in England
by: Catherine Quinot, et al.
Published: (2024-08-01)

Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies
by: Delphine Planas, et al.
Published: (2023-02-01)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
by: Xun Wang, et al.
Published: (2022-10-01)

The XBB.1.5 mRNA booster vaccine does not significantly increase the percentage of XBB.1.5 mono-reactive T cells
by: Joel Sop, et al.
Published: (2025-03-01)

Longitudinal Analysis of Humoral and Cellular Immune Response up to 6 Months after SARS-CoV-2 BA.5/BF.7/XBB Breakthrough Infection and BA.5/BF.7-XBB Reinfection
by: Xun Wang, et al.
Published: (2024-04-01)

BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
by: Rajesh M. Valanparambil, et al.
Published: (2023-11-01)

Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1
by: Yanping Hu, et al.
Published: (2023-12-01)

[1,1′-Bicyclohexane]-1,1′-diol
by: Zukisani Mtendeni, et al.
Published: (2023-11-01)

Efficacy of small molecules against the severe acute respiratory syndrome coronavirus 2 XBB1.16 and XBB1.9.2.1
by: Lunzhi Yuan, et al.
Published: (2024-03-01)

Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model
by: Cécile Hérate, et al.
Published: (2023-06-01)